SIG 220
Alternative Names: SIG-220Latest Information Update: 18 Aug 2023
At a glance
- Originator Sigilon Therapeutics
- Class Cell therapies; Gene therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Mucopolysaccharidosis VI
Most Recent Events
- 14 Aug 2023 Sigilon Therapeutics has been acquired by Eli Lilly and Company
- 22 May 2023 Early research in Mucopolysaccharidosis VI in USA (Parenteral) (Sigilon Therapeutics pipeline, May 2023)
- 10 Jun 2019 Sigilon Therapeutics has patent protection related to the Shielded Living Therapeutics™ platform in USA and other markets, as well as has pending applications in major markets